Market Price

58.89 

-0.19 -0.3%

as of Apr 25 '19

52 Week Range:

49.73 65.40


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 7.51
8.81
10.67
12.02
11.78
11.21
10.40
9.26
8.41
8.07
7.42
growth rate 17.3% 21.1% 12.7% -2.0% -4.8% -7.2% -11.0% -9.2% -4.0% -8.1%
Earnings BIT 5,343.41
6,654.64
6,759.29
7,614.97
4,752.43
6,842.00
4,203.00
4,071.00
3,747.00
3,587.00
1,750.00
growth rate 24.5% 1.6% 12.7% -37.6% 44.0% -38.6% -3.1% -8.0% -4.3% -51.2%
Avg.PE 9.79
9.07
8.10
6.28
9.43
28.90
54.75
18.43
16.76
20.19
36.71
growth rate -7.4% -10.7% -22.5% 50.2% 206.5% 89.5% -66.3% -9.1% 20.5% 81.8%
ROA 12.88
14.79
14.50
18.32
11.84
4.67
2.15
4.76
5.71
4.77
3.48
growth rate 14.8% -2.0% 26.3% -35.4% -60.6% -54.0% 121.4% 20.0% -16.5% -27.0%
ROE 39.76
41.13
36.71
42.98
26.81
10.89
5.75
14.82
20.99
20.13
15.71
growth rate 3.5% -10.8% 17.1% -37.6% -59.4% -47.2% 157.7% 41.6% -4.1% -22.0%
ROIC 21.15
31.76
30.49
31.78
21.20
8.70
5.43
10.17
12.73
12.05
9.13
growth rate 50.2% -4.0% 4.2% -33.3% -59.0% -37.6% 87.3% 25.2% -5.3% -24.2%
Cur. Ratio 1.21
1.35
1.50
1.49
1.37
1.27
0.96
1.08
0.87
0.80
0.95
growth rate 11.6% 11.1% -0.7% -8.1% -7.3% -24.4% 12.5% -19.4% -8.1% 18.8%
Quick Ratio 1.04
1.08
1.16
1.31
1.14
1.11
0.82
0.90
0.68
0.57
0.68
growth rate 3.9% 7.4% 12.9% -13.0% -2.6% -26.1% 9.8% -24.4% -16.2% 19.3%
Leverage 2.94
2.66
2.42
2.27
2.26
2.41
2.99
3.25
4.21
4.23
4.86
growth rate -9.5% -9.0% -6.2% -0.4% 6.6% 24.1% 8.7% 29.5% 0.5% 14.9%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 4,406.70
4,745.66
9,961.00
8,923.00
7,334.00
6,802.00
6,163.00
6,599.00
4,764.00
5,242.00
5,594.00
growth rate 7.7% 109.9% -10.4% -17.8% -7.3% -9.4% 7.1% -27.8% 10.0% 6.7%
Acct.Payable 2,257.00
2,155.00
2,449.00
2,499.00
3,492.00
3,469.00
1,680.00
2,285.00
1,720.00
growth rate -4.5% 13.6% 2.0% 39.7% -0.7% -51.6% 36.0% -24.7%
Cur.Assets 9,630.90
14,626.66
25,131.00
23,506.00
19,048.00
20,335.00
16,697.00
16,007.00
13,262.00
13,150.00
15,591.00
growth rate 51.9% 71.8% -6.5% -19.0% 6.8% -17.9% -4.1% -17.2% -0.8% 18.6%
Total Assets 28,493.96
33,808.75
56,127.00
52,830.00
53,534.00
55,899.00
58,595.00
60,056.00
62,526.00
63,354.00
60,651.00
growth rate 18.7% 66.0% -5.9% 1.3% 4.4% 4.8% 2.5% 4.1% 1.3% -4.3%
Cash 2,601.17
6,105.52
11,068.00
7,571.00
7,701.00
9,217.00
6,360.00
6,240.00
5,018.00
3,324.00
4,831.00
growth rate 134.7% 81.3% -31.6% 1.7% 19.7% -31.0% -1.9% -19.6% -33.8% 45.3%
Inventory 992.89
1,077.30
1,682.00
1,852.00
2,061.00
1,909.00
1,960.00
2,143.00
2,334.00
3,035.00
2,890.00
growth rate 8.5% 56.1% 10.1% 11.3% -7.4% 2.7% 9.3% 8.9% 30.0% -4.8%
Cur.Liabilities 8,141.56
10,859.18
16,787.00
15,752.00
13,903.00
16,051.00
17,330.00
14,869.00
15,256.00
16,383.00
16,292.00
growth rate 33.4% 54.6% -6.2% -11.7% 15.5% 8.0% -14.2% 2.6% 7.4% -0.6%
Liabilities 18,836.96
21,090.46
32,717.00
29,364.00
29,588.00
32,646.00
38,949.00
41,547.00
45,857.00
46,712.00
46,607.00
growth rate 12.0% 55.1% -10.3% 0.8% 10.3% 19.3% 6.7% 10.4% 1.9% -0.2%
LT Debt 90.43
5,774.94
9,097.00
7,338.00
9,347.00
8,517.00
8,337.00
14,110.00
14,612.00
15,564.00
17,363.00
growth rate 6,286.2% 57.5% -19.3% 27.4% -8.9% -2.1% 69.3% 3.6% 6.5% 11.6%
Equity 9,656.99
12,718.30
14,289.92
14,310.24
14,608.80
23,224.00
19,627.00
18,490.00
14,854.00
14,960.00
12,468.00
growth rate 31.7% 12.4% 0.1% 2.1% 59.0% -15.5% -5.8% -19.7% 0.7% -16.7%
Common Shares 1,453.00
1,450.00
1,446.00
1,367.00
1,264.00
1,254.00
1,264.00
1,265.00
1,266.00
1,267.00
1,267.00
growth rate -0.2% -0.3% -5.5% -7.5% -0.8% 0.8% 0.1% 0.1% 0.1% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 640.89
507.25
791.00
839.00
672.00
742.00
1,012.00
1,328.00
1,446.00
1,326.00
1,043.00
growth rate -20.9% 55.9% 6.1% -19.9% 10.4% 36.4% 31.2% 8.9% -8.3% -21.3%
Cash Dividends 1,662.30
1,832.64
2,069.03
2,317.12
2,256.17
3,461.00
3,521.00
3,486.00
3,561.00
3,519.00
3,484.00
growth rate 10.3% 12.9% 12.0% -2.6% 53.4% 1.7% -1.0% 2.2% -1.2% -1.0%
Cash From OA 5,305.52
7,226.53
10,680.00
7,821.00
6,948.00
7,400.00
7,058.00
3,324.00
4,145.00
3,578.00
2,618.00
growth rate 36.2% 47.8% -26.8% -11.2% 6.5% -4.6% -52.9% 24.7% -13.7% -26.8%
FCF per Share 2.21
3.75
3.81
3.22
1.14
2.87
2.35
1.00
0.35
1.66
1.22
growth rate 69.7% 1.6% -15.5% -64.6% 151.8% -18.1% -57.5% -65.0% 374.3% -26.5%
Sale Purchase of Stock 482.00
279.00
43.00
47.00
43.00
growth rate -42.1% -84.6% 9.3% -8.5%
FCF 4,703.00
8,782.00
8,499.00
6,524.00
2,329.00
5,342.00
4,306.00
536.00
1,831.00
1,958.00
1,247.00
growth rate 86.7% -3.2% -23.2% -64.3% 129.4% -19.4% -87.6% 241.6% 6.9% -36.3%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 19,178.65
20,194.14
33,269.00
33,591.00
27,973.00
25,806.00
26,547.00
24,708.00
23,002.00
22,465.00
22,090.00
growth rate 5.3% 64.8% 1.0% -16.7% -7.8% 2.9% -6.9% -6.9% -2.3% -1.7%
Op.Income 5,549.49
7,105.87
8,081.00
9,950.00
6,270.00
6,842.00
4,203.00
4,071.00
3,747.00
3,587.00
1,750.00
growth rate 28.1% 13.7% 23.1% -37.0% 9.1% -38.6% -3.1% -8.0% -4.3% -51.2%
IBT 5,268.50
6,652.79
6,757.44
7,613.13
4,706.88
3,267.00
1,246.00
3,069.00
3,552.00
2,227.00
1,993.00
growth rate 26.3% 1.6% 12.7% -38.2% -30.6% -61.9% 146.3% 15.7% -37.3% -10.5%
Net Income 3,702.70
4,629.93
8,081.00
9,950.00
6,270.00
2,556.00
1,233.00
2,825.00
3,499.00
3,001.00
2,155.00
growth rate 25.0% 74.5% 23.1% -37.0% -59.2% -51.8% 129.1% 23.9% -14.2% -28.2%
EPS 4.20
5.19
5.57
7.25
4.94
2.04
0.98
2.23
2.76
2.37
1.70
growth rate 23.6% 7.3% 30.2% -31.9% -58.7% -52.0% 127.6% 23.8% -14.1% -28.3%
Gross Profit 15,174.32
16,639.05
27,152.00
27,488.00
22,716.00
20,671.00
20,812.00
20,220.00
19,006.00
18,328.00
17,586.00
growth rate 9.7% 63.2% 1.2% -17.4% -9.0% 0.7% -2.8% -6.0% -3.6% -4.1%
R&D 3,143.14
2,714.18
3,273.76
3,399.96
3,227.59
4,281.00
5,001.00
5,660.00
5,679.00
5,455.00
5,299.00
growth rate -13.7% 20.6% 3.9% -5.1% 32.6% 16.8% 13.2% 0.3% -3.9% -2.9%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 925.00
382.00
855.00
725.00
489.00
growth rate -58.7% 123.8% -15.2% -32.6%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 5,242.00
6,007.00
5,521.00
5,819.00
5,594.00
growth rate 14.6% -8.1% 5.4% -3.9%
Acct.Payable 3,611.00
11,481.00
10,913.00
10,992.00
1,720.00
growth rate 218.0% -5.0% 0.7% -84.4%
Cur.Assets 13,150.00
13,182.00
12,449.00
13,108.00
15,591.00
growth rate 0.2% -5.6% 5.3% 18.9%
Total Assets 63,354.00
63,281.00
61,344.00
61,443.00
60,651.00
growth rate -0.1% -3.1% 0.2% -1.3%
Cash 3,324.00
3,005.00
2,978.00
3,420.00
4,831.00
growth rate -9.6% -0.9% 14.8% 41.3%
Inventory 3,035.00
3,283.00
3,118.00
3,027.00
2,890.00
growth rate 8.2% -5.0% -2.9% -4.5%
Cur.Liabilities 16,383.00
18,164.00
17,201.00
15,248.00
16,292.00
growth rate 10.9% -5.3% -11.4% 6.9%
Liabilities 46,712.00
48,708.00
47,072.00
47,906.00
46,607.00
growth rate 4.3% -3.4% 1.8% -2.7%
LT Debt 15,564.00
15,694.00
15,456.00
18,424.00
17,363.00
growth rate 0.8% -1.5% 19.2% -5.8%
Equity 14,960.00
12,915.00
12,645.00
11,936.00
12,468.00
growth rate -13.7% -2.1% -5.6% 4.5%
Common Shares 317.00
317.00
317.00
317.00
317.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 477.00
213.00
273.00
242.00
315.00
growth rate -55.4% 28.2% -11.4% 30.2%
Cash Dividends 2,363.00
2,363.00
1,121.00
1,121.00
growth rate 0.0% -52.6% 0.0%
Cash From OA 997.00
-140.00
65.00
469.00
2,224.00
growth rate -100.0% 100.0% 621.5% 374.2%
Sale Purchase of Stock 13.00
14.00
2.00
growth rate 7.7% -85.7%
FCF 520.00
-353.00
-208.00
227.00
1,909.00
growth rate -100.0% 0.0% 100.0% 741.0%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 5,777.00
5,178.00
5,155.00
5,340.00
6,417.00
growth rate -10.4% -0.4% 3.6% 20.2%
Op.Income 925.00
382.00
855.00
725.00
489.00
growth rate -58.7% 123.8% -15.2% -32.6%
IBT 407.00
374.00
412.00
477.00
730.00
growth rate -8.1% 10.2% 15.8% 53.0%
Net Income 1,301.00
340.00
350.00
431.00
1,034.00
growth rate -73.9% 2.9% 23.1% 139.9%
EPS
growth rate
Gross Profit 4,605.00
4,076.00
4,166.00
4,209.00
5,135.00
growth rate -11.5% 2.2% 1.0% 22.0%
R&D 1,426.00
1,252.00
1,331.00
1,242.00
1,474.00
growth rate -12.2% 6.3% -6.7% 18.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (5.52)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 36.15 34.64 16.09
EPS / Growth -4.6% 1.70 5.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 2.00 18.08 18.08
Future EPS 1.88 1.88 1.88
Value Price
MOS %
0.93
-98.4%
8.39
-85.7%
8.39
-85.7%
MOS Price 0.46 4.20 4.20
IRT 29.64 29.64 29.64

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.